MedTrace Logo

Effect of Gastric Bypass Surgery on Pancreatic Islets and Incretin Function

NCT01559779 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2014-06-10

No results posted yet for this study

Summary

The study aims at describing the acute and subacute changes after Roux-en-Y (RYGB) gastric bypass in insulin secretion from the beta cell and glucagon secretion from the alpha cell as well as the stimulatory effect of the incretins on the pancreatic islets. RYGB is a bariatric procedure that changes the gastrointestinal anatomy and has been demonstrated to cause remission of type 2 diabetes shortly after the operation, before any significant weight loss. The altered transit of nutrient through the gastrointestinal tract after the operation is thought to play a key role in this remission and studies have shown significant changes in the secretion of gut hormones, namely the incretin hormone glucagon-like peptide-1 (GLP-1). However it is unknown whether the secretory function of the pancreatic islets as well as the stimulatory effect of the incretin hormones is changes postoperatively.

Conditions

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Carsten Dirksen, MD · Hvidovre University Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-07-31
Completion
2012-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01559779 on ClinicalTrials.gov